SCHEMBL6280397

SCHEMBL6280397

C=CCc1ccc(N)c2ncccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
MAPT P10636 2/20 0.54
APAF1 O14727 1/20 0.54
TDP2 O95551 1/20 0.54
ALDH1A1 P00352 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54
SENP6 Q9GZR1 1/20 0.54
HSP90AA1 P07900 3/20 0.44
HSP90AB1 P08238 3/20 0.44
IDO1 P14902 1/20 0.44
PSMB5 P28074 1/20 0.44
HTT P42858 3/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9280481 0.86 KDM4E (0.47) KMT2AMAPTALDH1A1HSP90AA1HTT
SCHEMBL19882146 0.81 ALOX15 (0.45) MEN1KMT2AMAPTAPAF1TDP2
SCHEMBL6892279 0.81 KDM4E (0.68) KMT2AMAPTALDH1A1HTTKDM4E
SCHEMBL31106423 0.81 KDM4E (0.68) KMT2AMAPTALDH1A1HTTKDM4E
SCHEMBL3440638 0.75 IDO1 (0.42) MEN1KMT2AMAPTALDH1A1IDO1
SCHEMBL7455899 0.74 HSP90AA1 (0.70) MEN1KMT2AMAPTAPAF1TDP2
SCHEMBL29661959 0.74 HSP90AA1 (0.70) MEN1KMT2AMAPTAPAF1TDP2
SCHEMBL6280264 0.74 IMPDH2 (0.38) IMPDH2
SCHEMBL12533508 0.73 CCR1 (0.53) MEN1KMT2AMAPTALDH1A1HSP90AA1
SCHEMBL11190488 0.73 CDK1 (0.46) MEN1KMT2AMAPTALDH1A1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 MEN1 2478/4885KMT2A 261/4885MAPT 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.